Portfolio: Investments By Stage
As the current collection demonstrates, MPM is committed to participating and succeeding across the life-cycle spectrum of companies. We invest in companies that range from research to commercial, with an emphasis on early-stage human proof-of-concept assets. MPM's portfolio consists of over 150 drugs and 23 devices in development or in the market. We believe we have assembled an experienced team with capabilities across the continuum from research to commercial.